What is the role of galactose in the treatment of pediatric nephrotic syndrome?

Updated: Mar 04, 2020
  • Author: Jerome C Lane, MD; Chief Editor: Craig B Langman, MD  more...
  • Print

Some patients with FSGS have an incompletely characterized circulating permeability factor (FSPF) that has been associated with recurrence of FSGS after kidney transplantation. Galactose has a high affinity for FSPF. An adult patient with FSPF-positive FSGS who was treatment-resistant was given galactose (10 g orally twice daily). [93] He achieved complete remission of proteinuria within 7 months and, 2 years later, remained in complete remission (on a higher dose of 15 g orally twice daily).

In one small study, 7 children with SRNS and positive FSPF activity were treated with oral galactose (0.2 g/kg twice daily) for 16 weeks. Despite a decrease in FSPF, no reduction in proteinuria was demonstrated. [94]

Further studies are needed before the routine use of galactose can be recommended, and its safety and efficacy in children are unknown.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!